search
Back to results

Balloon Prophylaxis of Aneurysmal Vasospasm

Primary Purpose

Aneurysm, Vasospasm

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
transluminal ballooning
currently existing therapies for the treatment of vasospasm
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Aneurysm focused on measuring aneurysm, vasospasm, subarachnoid hemorrhage, transluminal ballooning

Eligibility Criteria

17 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Fisher grade III hemorrhage Documented ruptured cerebral aneurysm via angiography, CT angiogram or any other acceptable neuroradiologic means Ruptured aneurysm(s) secured Ballooning available < 96 hours post SAH Exclusion Criteria: Vasospasm prior to randomization Interventionalist unavailable Patient outside the 96 hour window for ballooning Enrolled in competing trial Unsecured aneurysms (symptomatic or asymptomatic) that are in the location where the ballooning procedure would occur Medical conditions known that would effect mortality / morbidity Severe Cerebrovascular atherosclerosis > 16 years old.

Sites / Locations

  • Coordinating Center: University of California, Davis Medical Center, Department of Neurological Surgery
  • Vanderbilt University Medical Center
  • University of Washington - Harborview Medical Center
  • University of Toronto
  • University Medical Center Utrecht, Trialbeureau Neurodivisie, Heidelberglaan 100

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

pTBA

Control

Arm Description

Prophylactic Transluminal Ballooning Angioplasty

currently existing therapies for the treatment of vasospasm

Outcomes

Primary Outcome Measures

Dichotomized Glasgow Outcome Scale (GOS)assessed at 3 months by a blinded evaluator

Secondary Outcome Measures

Dichotomized GOS at 6 months, assessment at 3 and 6 months of: five-point GOS; GOS - Extended (GOSE), occurrence of delayed ischemic deficit (DID), the incidence of severe vasospasm as detected by Transcranial Doppler (TCD) Ultrasonography (mean blood f

Full Information

First Posted
January 26, 2006
Last Updated
February 13, 2017
Sponsor
University of California, Davis
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00282893
Brief Title
Balloon Prophylaxis of Aneurysmal Vasospasm
Official Title
Balloon Prophylaxis of Aneurysmal Vasospasm
Study Type
Interventional

2. Study Status

Record Verification Date
March 2014
Overall Recruitment Status
Completed
Study Start Date
October 2000 (undefined)
Primary Completion Date
September 2006 (Actual)
Study Completion Date
December 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine if early transluminal ballooning of the major cerebral arteries prevents severe vasospasm and improves neurological outcome in patients with Fisher Grade III aneurysmal subarachnoid hemorrhage.
Detailed Description
Aneurysmal subarachnoid hemorrhage (SAH) afflicts over 30,000 patients a year in the United States. Fifteen percent of those who survive the initial bleeding die or suffer disabilities because of delayed ischemic deficit (stroke) due to vasospasm. Vasospasm is a condition in which the arteries in the brain constrict, not allowing sufficient blood flow and oxygenation. Research on the pharmacological prevention and treatment of vasospasm has resulted in only minimal improvement for this problem. Transluminal ballooning is a procedure that opens blood vessels, allowing blood flow and oxygen to get to the brain more easily. Researchers believe that this dilation of the blood vessels lasts for at least 7 days. This procedure is used to treat severe vasospasm although it is not commonly used to prevent vasospasm. The purpose of this trial is to find out if this procedure, performed immediately after the aneurysm is secured, prevents spasm in the brain and improves patient outcome. Eligible SAH patients whose aneurysm has been repaired by neurosurgical or endovascular procedure and who are enrolled in the study will be randomized to receive either the prophylactic transluminal ballooning procedure or to receive standard care, which includes currently existing therapies for the treatment of vasospasm. Participants will be asked to return for follow-up examinations at 3 and 6 months to evaluate recovery using a standardized outcome scale.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aneurysm, Vasospasm
Keywords
aneurysm, vasospasm, subarachnoid hemorrhage, transluminal ballooning

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
pTBA
Arm Type
Experimental
Arm Description
Prophylactic Transluminal Ballooning Angioplasty
Arm Title
Control
Arm Type
Active Comparator
Arm Description
currently existing therapies for the treatment of vasospasm
Intervention Type
Procedure
Intervention Name(s)
transluminal ballooning
Intervention Type
Other
Intervention Name(s)
currently existing therapies for the treatment of vasospasm
Primary Outcome Measure Information:
Title
Dichotomized Glasgow Outcome Scale (GOS)assessed at 3 months by a blinded evaluator
Secondary Outcome Measure Information:
Title
Dichotomized GOS at 6 months, assessment at 3 and 6 months of: five-point GOS; GOS - Extended (GOSE), occurrence of delayed ischemic deficit (DID), the incidence of severe vasospasm as detected by Transcranial Doppler (TCD) Ultrasonography (mean blood f

10. Eligibility

Sex
All
Minimum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Fisher grade III hemorrhage Documented ruptured cerebral aneurysm via angiography, CT angiogram or any other acceptable neuroradiologic means Ruptured aneurysm(s) secured Ballooning available < 96 hours post SAH Exclusion Criteria: Vasospasm prior to randomization Interventionalist unavailable Patient outside the 96 hour window for ballooning Enrolled in competing trial Unsecured aneurysms (symptomatic or asymptomatic) that are in the location where the ballooning procedure would occur Medical conditions known that would effect mortality / morbidity Severe Cerebrovascular atherosclerosis > 16 years old.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Paul Muizelaar, MD, PhD
Organizational Affiliation
Professor and Chairman, Department of Neurological Surgery, University of California, Davis
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jonathan Hartman, MD
Organizational Affiliation
Interventional Neuroradiologist, University of California, Davis
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marike Zwienenberg, MD
Organizational Affiliation
University of California, Davis
Official's Role
Principal Investigator
Facility Information:
Facility Name
Coordinating Center: University of California, Davis Medical Center, Department of Neurological Surgery
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232-2380
Country
United States
Facility Name
University of Washington - Harborview Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98014
Country
United States
Facility Name
University of Toronto
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5B-1A6
Country
Canada
Facility Name
University Medical Center Utrecht, Trialbeureau Neurodivisie, Heidelberglaan 100
City
Utrecht
ZIP/Postal Code
3584 CX
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
18420953
Citation
Zwienenberg-Lee M, Hartman J, Rudisill N, Madden LK, Smith K, Eskridge J, Newell D, Verweij B, Bullock MR, Baker A, Coplin W, Mericle R, Dai J, Rocke D, Muizelaar JP; Balloon Prophylaxis for Aneurysmal Vasospasm (BPAV) Study Group. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008 Jun;39(6):1759-65. doi: 10.1161/STROKEAHA.107.502666. Epub 2008 Apr 17.
Results Reference
result

Learn more about this trial

Balloon Prophylaxis of Aneurysmal Vasospasm

We'll reach out to this number within 24 hrs